Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
Public ClinicalTrials.gov record NCT00916617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.
Study identification
- NCT ID
- NCT00916617
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Aug 31, 2012
- Completion
- Aug 31, 2012
- Last update posted
- May 31, 2017
2009 – 2012
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Alzheimer's Institute | Phoenix | Arizona | 85006 | — |
| Pharmacology Research Institute | Encino | California | 91316 | — |
| Brain Matters Research | Delray Beach | Florida | 33445 | — |
| MD Clinical | Hallandale | Florida | 33009 | — |
| Palm Beach Neurology - Premiere Research Institute | West Palm Beach | Florida | 33407 | — |
| Neurostudies.net | Decatur | Georgia | 30033 | — |
| Dekalb Neurology Associates, LLC | Lawrenceville | Georgia | 30045 | — |
| NeuroStudies.net | Lawrenceville | Georgia | 30046 | — |
| Clinical Research Institute | Wichita | Kansas | 67207 | — |
| Monroe Community Hospital | Rochester | New York | 14620 | — |
| Rhode Island Mood and Memory Research Institute | East Providence | Rhode Island | 02914 | — |
| Butler Hospital | Providence | Rhode Island | 02906 | — |
| Texas Neurology, P.A. | Dallas | Texas | 75214 | — |
| The Memory Clinic | Bennington | Vermont | 05201 | — |
| University of Wisconsin, Department of Surgery | Madison | Wisconsin | 53705 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00916617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2017 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00916617 live on ClinicalTrials.gov.